Asparaginase Escherichia coli
- Generic Name
- Asparaginase Escherichia coli
- Brand Names
- Rylaze, Spectrila
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 9015-68-3
- Unique Ingredient Identifier
- G4FQ3CKY5R
- Background
Asparaginase derived from Escherichia coli (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from E. coli has clinically shown to exh...
- Indication
Indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL).
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL)
- Associated Therapies
- -
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 36
- Registration Number
- NCT00003783
- Locations
- 🇺🇸
West Virginia University Medical School, Charleston Division, Charleston, West Virginia, United States
🇺🇸Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
Radiation Therapy to the Head or Intrathecal Chemotherapy Plus High Dose Cytarabine in Preventing CNS Disease in Children With Acute Lymphoblastic Leukemia
- Conditions
- Locations
- 🇮🇳
Tata Memorial Centre, Mumbai, India
🇮🇳Cancer Institute (W.I.A.), Madras, India
🇮🇳All-India Institute of Medical Sciences, New Delhi, India
Combination Chemotherapy in Treating Adults With Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Johann Wolfgang Goethe University Hospital
- Registration Number
- NCT00002531
- Locations
- 🇩🇪
Klinikum der J.W. Goethe Universitaet, Frankfurt, Germany
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2013-08-07
- Lead Sponsor
- Hannover Medical School
- Registration Number
- NCT00002532
- Locations
- 🇩🇪
Medizinische Hochschule Hannover, Hannover, Germany
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-11-24
- Last Posted Date
- 2013-08-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 2078
- Registration Number
- NCT00002812
- Locations
- 🇺🇸
Children's Hospital of Columbus, Columbus, Ohio, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
- Conditions
- First Posted Date
- 2003-10-07
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 350
- Registration Number
- NCT00070174
- Locations
- 🇺🇸
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, United States
🇺🇸St. Barnabas Medical Center, Livingston, New Jersey, United States
🇺🇸All Children's Hospital, St. Petersburg, Florida, United States
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳Kidwai Memorial Institute of Oncology, Bangalore, India
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: allopurinolDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: vincristine sulfateDrug: dexamethasoneDrug: asparaginaseBiological: filgrastimDrug: imatinib mesylateDrug: methotrexateDrug: cytarabineDrug: trimethoprim-sulfamethoxazoleDrug: mercaptopurineDrug: leucovorin calciumBiological: alemtuzumabDrug: acyclovirOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT00061945
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2003-04-30
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 2000
- Registration Number
- NCT00003436
- Locations
- 🇬🇧
Christie Hospital N.H.S. Trust, Manchester, England, United Kingdom
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.